Meldungen zum Thema Health

12.07.2016 – 01:10
Shire Pharmaceuticals Group Plc
Regulatory Approval - FDA Approves Shire's Xiidra(TM) (lifitegrast ophthalmic solution) 5% - The Only Treatment Indicated for the Signs and Symptoms of Dry Eye Disease
Lexington, Massachusetts (ots/PRNewswire) - - An estimated 16 million people in the U.S. are diagnosed with dry eye disease - Xiidra is the first prescription eye drop FDA-approved to treat both the signs and symptoms of dry eye disease - U.S. launch of Xiidra planned for third quarter 2016 Shire plc (LSE: SHP, ...
mehr
11.07.2016 – 18:01
Novo Nordisk
Novo Nordisk to Present 28 Abstracts at the World Federation of Hemophilia Congress
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk announced today that data from 28 abstracts will be shared at the upcoming World Federation of Hemophilia World Congress (WFH) in Orlando, Florida, from 24-28 July. The WFH Congress is the largest ...
mehr
07.07.2016 – 08:01
Shire Pharmaceuticals Group Plc
Shire Receives Extension of Market Authorization in Europe for Revestive (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS)
Zug, Switzerland (ots/PRNewswire) - This press release is intended for a global audience. First therapy indicated in the EU for use in patients aged one year and above with SBS, a rare gastrointestinal condition Shire (LSE: SHP, NASDAQ: SHPG) today announced that the European Commission has granted extension of ...
mehr
01.07.2016 – 10:43
Merck Healthcare Germany
Results of Pivotal TAILOR Study Confirm Addition of Erbitux to FOLFOX Significantly Improves Outcomes in RAS Wild-Type Metastatic Colorectal Cancer
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media WCGC Abstract # 0-025; poster presentation, July 1, 2016, 10:35 am CEST - Phase III study shows response rate of 61.1% for patients treated with Erbitux plus FOLFOX - 31% decrease in risk of disease progression and 24% decrease in risk of ...
mehr
01.07.2016 – 08:19
LEO Pharma
LEO Pharma Enters Biologics Through Strategic Partnership With AstraZeneca
Ballerup, Denmark (ots/PRNewswire) - LEO Pharma is a significant step closer to realising its vision of becoming the preferred dermatology care partner following a strategic partnership with AstraZeneca announced today. (Logo: http://photos.prnewswire.com/prnh/20130221/595427 ) The partnership covers potential new medicines for atopic dermatitis and psoriasis, two of ...
mehr
30.06.2016 – 13:01
Shire Pharmaceuticals Group Plc
Shire Announces Top-Line Results for Phase 2 Trial of SHP607 in Extremely Premature Infants
Lexington, Massachusetts (ots/PRNewswire) - - Top-line SHP607 study results in extremely premature infants showed no impact on primary endpoint of reducing the severity of Retinopathy of Prematurity - Top-line analysis of secondary endpoints showed clinically relevant effects on severe complications related to lung and brain damage - These data support further ...
mehr

28.06.2016 – 14:03
Norgine GmbH
Norgine Completes the Divestment of Its Middle East and North Africa (MENA) Operations and Product Rights to Acino
London (ots/PRNewswire) - Norgine B.V. today announced that it has completed the divestment of its MENA operations and product rights for MOVICOL®, MOVIPREP®, KLEAN-PREP® and NORMACOL® in MENA to Acino. (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) Peter Stein, CEO at Norgine said: "The divestment ...
mehr
28.06.2016 – 07:01
Novo Nordisk
EMA Grants Marketing Authorisation of mylife(TM) YpsoPump® for Use with NovoRapid® PumpCart®, Marking the Start of a Collaboration Between Novo Nordisk and Ypsomed
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announces the European Medicines Agency (EMA) marketing approval of the mylife(TM) YpsoPump® insulin pump for use with prefilled pump ...
mehr
27.06.2016 – 12:32
Accuray Europe
Accuray Receives 510(k) FDA Clearance for the Radixact(TM) Image-Guided Radiation Therapy Platform and Integrated Software
Sunnyvale, California (ots/PRNewswire) - Next Generation "Smart" System Enables Clinicians to Provide Highly Precise Treatment, Efficiently, for More Patients, Every Day Accuray Incorporated (NASDAQ: ARAY) announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ...
mehr
20.06.2016 – 14:10
Jacoti bvba
Jacoti to Present Award-winning Hearing Technologies at HLAA/IFOH '16 and Simons Foundation
Washington (ots/PRNewswire) - Jacoti bvba's innovative approach and products continue to attract worldwide attention in the rapidly-growing area of hearing personalization and hearing loss compensation for mobile devices. (Logo: http://photos.prnewswire.com/prnh/20160620/381050LOGO ) (Photo: http://photos.prnewswire.com/prnh/20160620/381051 ) Jacoti will present and ...
mehr
16.06.2016 – 12:31
Accuray Europe
United Kingdom's NHS Supply Chain to Acquire Seven TomoTherapy® Systems
Sunnyvale, California (ots/PRNewswire) - Largest Ever Accuray Deal Will Provide More Cancer Patients in the United Kingdom (UK) Access to Advanced, Precise Radiation Treatments Accuray Incorporated (NASDAQ: ARAY) has a signed deal with NHS Supply Chain for seven TomoTherapy® Systems in a new partnership designed to provide clinicians and their patients with additional ...
mehr
16.06.2016 – 11:40
Copernicus Atmosphere Monitoring Service (CAMS)
Copernicus Atmosphere Monitoring Service (CAMS) Announces a Major Improvement on Atmosphere Data Accessibility
Athens, Greece (ots/PRNewswire) - At the first CAMS summit in Athens on 14-16 June, ECMWF, in charge of CAMS on behalf of the European Commission, will launch a radically new interactive and ready to use version of its online platform of atmosphere data. Policy makers, scientific and business communities or citizens ...
mehr

13.06.2016 – 23:16
Novo Nordisk
Victoza® significantly reduced the risk of major cardiovascular events and death in adults with type 2 diabetes in the LEADER trial
New Orleans (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that Victoza® (liraglutide) significantly reduced the risk of the composite primary endpoint of cardiovascular (CV) death, non-fatal ...
mehr
13.06.2016 – 16:01
Novo Nordisk
Faster-acting insulin aspart showed a statistically significant reduction in HbA1c in type 1 diabetes and a comparable HbA1c reduction in type 2 diabetes versus NovoRapid® (insulin aspart)
New Orleans (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstracts: 293-OR, 240-OR Faster-acting insulin aspart improved postprandial glucose (PPG) control in type 1 and type 2 diabetes New phase 3a findings showed that ...
mehr
13.06.2016 – 09:03
Merck Healthcare Germany
Merck in Agreement with HAPPYneuron to Offer First-of-its-Kind e-Health Solution for People Living with Multiple Sclerosis
Darmstadt, Germany (ots/PRNewswire) - - Agreement provides Merck with exclusive license to cognitive remediation training programs - HAPPYneuron will be available for inclusion in Merck's MSdialog platform for use with Rebif® (interferon beta-1a) Merck, a leading science and technology company, announced today that ...
mehr
12.06.2016 – 16:16
Novo Nordisk
Semaglutide Demonstrated Superior Improvements in Glycaemic Control vs Sitagliptin (SUSTAIN 2) and Exenatide ER (SUSTAIN 3) in Two Clinical Trials in Adults With Type 2 Diabetes
New Orleans (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstracts 185-OR and 187-OR Findings from two phase 3a clinical trials for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, were presented ...
mehr
11.06.2016 – 17:01
sanofi-aventis Group
Successful Switch to Sanofi's Toujeo® Evaluated in a Real-World Setting
Paris (ots/PRNewswire) - Sanofi announced today the release of the new real world data assessing the use of Toujeo® (insulin glargine injection 300 Units/mL). The U.S. Predictive Health Intelligence Environment (PHIE) database, containing a substantial amount of patient level information, was analyzed to assess Toujeo in this real life setting. The study examined ...
mehr
11.06.2016 – 17:01
Novo Nordisk
Tresiba® (insulin degludec injection U-100) demonstrated significantly lower rates of overall, nocturnal and severe hypoglycaemia vs insulin glargine U-100
New Orleans (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstracts 87-LB and 90-LB New findings from the two phase 3b SWITCH trials showed that treatment with long-acting basal insulin Tresiba® (insulin degludec injection ...
mehr

10.06.2016 – 21:13
Shire Pharmaceuticals Group Plc
Shire Announces Completion of Decentralized Procedure in Europe for Immunoglobulin Treatment Cuvitru
Zug, Switzerland (ots/PRNewswire) - - Cuvitru (IG 20mg/ml solution for subcutaneous injection) builds on company's broad portfolio of IG treatments gained through combination with Baxalta - New option to treat primary and certain secondary immunodeficiencies can help meet patient needs related to number of infusion ...
mehr
10.06.2016 – 15:18
ViiV Healthcare
ViiV Healthcare Announces FDA Approval to Lower the Weight Limit for dolutegravir in Children and Adolescents Living With HIV
London (ots/PRNewswire) - Reduction of weight limit to at least 30kg means more children and adolescents will be eligible for dolutegravir ViiV Healthcare today announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for dolutegravir 10mg and 25mg oral ...
mehr
10.06.2016 – 07:01
UCB Pharma
UCB's bimekizumab demonstrates positive results in early development in patients with psoriatic arthritis
Brussels (ots/PRNewswire) - - Bimekizumab is a highly selective monoclonal antibody that inhibits the activity of both IL-17A and IL-17F, key pro-inflammatory cytokines expressed in several inflammatory diseases[1],[2] - In this early proof of concept study, bimekizumab showed fast and sustained efficacy on disease ...
mehr
08.06.2016 – 00:02
UCB Pharma
UCB Commitment to Addressing Real World Patient Needs on Display at the Annual European Congress of Rheumatology (EULAR 2016)
Brussels (ots/PRNewswire) - For medical and trade media only. New data highlight breadth of UCB's pioneering portfolio with four molecules across five indications: - An oral presentation of data from the two year C-EARLY(TM) Phase 3 study of Cimzia®, exploring different dosing strategies - Oral presentations from ...
mehr
07.06.2016 – 17:17
Debiopharm International SA
Debiopharm International SA Initiates Clinical Phase II Study Evaluating Debio 1143 in Ovarian Cancer
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm today announced the start of a phase II clinical trial for Debio 1143 in combination with standard of care Carboplatin and Paclitaxel in Epithelial Ovarian Cancer Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global ...
mehr
06.06.2016 – 13:36
Novo Nordisk
Novo Nordisk to Present 53 Abstracts at 76th Annual American Diabetes Association Scientific Sessions in New Orleans, LA
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk, a global leader in diabetes care, today announced that data from 53 abstracts including 8 oral presentations will be shared at the upcoming 76th ...
mehr

06.06.2016 – 06:00
JSS Medical Research Inc.
JSS Medical Research Establishes Its Presence in Europe
Montreal (ots/PRNewswire) - - JSS Medical Research, an international contract research organization active in over 20 countries acquires Bonne Santé in Poland as catalyst for European expansion JSS Medical Research Inc., an International Contract Research Organization (CRO) with offices in Canada, Latin America and Asia/Pacific, announced the acquisition of Bonne Santé, a Polish CRO, to accelerate the expansion into ...
mehr
04.06.2016 – 15:09
Merck Healthcare Germany
Merck Partners with Array BioPharma and Pierre Fabre to Initiate BRAF-mutant CRC Phase III Trial
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - BEACON CRC trial will assess efficacy of combination regime Erbitux® (cetuximab), binimetinib and encorafenib in BRAF-mutant metastatic colorectal cancer (mCRC) Merck, a leading science and technology company, jointly announced with ...
mehr
02.06.2016 – 18:01
Novo Nordisk
Three-year Data Show Early Response to Saxenda® Resulted in Improvements in Weight Loss and Cardiometabolic Risk Factors
Gothenburg, Sweden (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Poster# PP3.09 Today, data from a post hoc analysis of the three-year part of the phase 3a SCALE(TM) (Satiety and Clinical Adiposity - Liraglutide Evidence) ...
mehr
02.06.2016 – 14:03
Isofol Medical AB
Isofol Medical Has Successfully Advanced to the Next Dose Level of Modufolin® in a Phase I/II Clinical Trial in Colorectal Cancer
Gothenburg, Sweden (ots/PRNewswire) - Isofol Medical AB today announced initiation of the next dose level of Modufolin®, in combination with 5-FU and oxaliplatin or 5-FU and irinotecan, in the ongoing, incremental dose cohort, phase I/II clinical trial, ISO-CC-005. In total 16 patients with stage IV colorectal ...
mehr
02.06.2016 – 09:02
Debiopharm International SA
FDA Grants Orphan Drug Designation to Debiopharm International SA's IAP Inhibitor Debio 1143 in the Treatment of Ovarian Cancer
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), a Swiss-based company, part of Debiopharm Group(TM), today announced that the FDA Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation to Debio 1143 for treatment of ovarian cancer. Orphan Drug Designation ...
mehr
31.05.2016 – 15:02
ViiV Healthcare and the International Association of Providers of AIDS Care (IAPAC)
ViiV Healthcare and the International Association of Providers of AIDS Care (IAPAC) to Collaborate on Fast-Track Cities
London and Washington (ots/PRNewswire) - Collaboration will focus on 16 cities where HIV is highly prevalent and will help monitor progress towards the attainment of UNAIDS 90-90-90 and zero discrimination and stigma targets ViiV Healthcare and the International Association of Providers of AIDS Care (IAPAC) today ...
mehr

Vorherige34353637383940414243Nächste